Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 30;14(23):5926.
doi: 10.3390/cancers14235926.

Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment

Asmaa Elrakaybi  1   2 , Dietrich A Ruess  3   4 , Michael Lübbert  1   4 , Michael Quante  4   5 , Heiko Becker  1   4
Affiliations
Review

Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment

Asmaa Elrakaybi et al. Cancers (Basel). .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with high potential of metastases and therapeutic resistance. Although genetic mutations drive PDAC initiation, they alone do not explain its aggressive nature. Epigenetic mechanisms, including aberrant DNA methylation and histone modifications, significantly contribute to inter- and intratumoral heterogeneity, disease progression and metastasis. Thus, increased understanding of the epigenetic landscape in PDAC could offer new potential biomarkers and tailored therapeutic approaches. In this review, we shed light on the role of epigenetic modifications in PDAC biology and on the potential clinical applications of epigenetic biomarkers in liquid biopsy. In addition, we provide an overview of clinical trials assessing epigenetically targeted treatments alone or in combination with other anticancer therapies to improve outcomes of patients with PDAC.

Keywords: BET inhibitors; DNMT inhibitors; EZH2 inhibitors; HDAC inhibitors; cfDNA methylation; epigenetics; pancreatic ductal adenocarcinoma; retinoids.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Development of new biomarkers and therapeutic approaches for cancer treatment: A bi-directional process. Bench to bedside; Experimental models used in cancer research can vary from 2D-cell culture to murine in vivo models to more complex 3D patient-derived cancer organoids. These models can identify cancer-related genetic and epigenetic signatures using a plethora of sequencing and targeted qPCR techniques, which can then be utilized to predict novel cancer biomarkers and therapeutic targets to be eventually translated into clinical practice. Bedside to bench; the poor performance of some biomarkers or the emergence of drug resistance to anticancer agents may contribute to their failure to reach the clinic. This urges preclinical studies to test new biomarker panels or to find new strategies to overcome drug resistance with the aim to improve therapeutic outcomes of cancer patients.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Schouten T.J., Daamen L.A., Dorland G., van Roessel S.R., Groot V.P., Besselink M.G., Bonsing B.A., Bosscha K., Brosens L.A.A., Busch O.R., et al. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann. Surg. Oncol. 2022;29:5988–5999. doi: 10.1245/s10434-022-11664-4. - DOI - PMC - PubMed
    1. Catalano M., Aprile G., Conca R., Petrioli R., Ramello M., Roviello G. The Impact of Age, Performance Status and Comorbidities on Nab-Paclitaxel plus Gemcitabine Effectiveness in Patients with Metastatic Pancreatic Cancer. Sci. Rep. 2022;12:8244. doi: 10.1038/s41598-022-12214-4. - DOI - PMC - PubMed
    1. Balaban E.P., Mangu P.B., Yee N.S. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J. Oncol. Pract. 2017;13:265–269. doi: 10.1200/JOP.2016.017376. - DOI - PubMed
    1. Singh R.R., O’Reilly E.M. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs. 2020;80:647–669. doi: 10.1007/s40265-020-01304-0. - DOI - PMC - PubMed

LinkOut - more resources